東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

The Effect of Aquaporin-7 on Breast ...

Charlestin, Verodia,

FindBook

Google Book

Amazon

博客來

The Effect of Aquaporin-7 on Breast Cancer Progression and Therapeutic Resistance /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	The Effect of Aquaporin-7 on Breast Cancer Progression and Therapeutic Resistance // Verodia Charlestin.
作者:	Charlestin, Verodia,
面頁冊數:	1 electronic resource (289 pages)
附註:	Source: Dissertations Abstracts International, Volume: 85-06, Section: B.
Contained By:	Dissertations Abstracts International85-06B.
標題:	Biochemistry. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=30689683
ISBN:	9798381153095

The Effect of Aquaporin-7 on Breast Cancer Progression and Therapeutic Resistance /
Charlestin, Verodia,

The Effect of Aquaporin-7 on Breast Cancer Progression and Therapeutic Resistance /Verodia Charlestin. - 1 electronic resource (289 pages)

Source: Dissertations Abstracts International, Volume: 85-06, Section: B.

The complex yet interrelated connections between cancer metabolism, gene expression, and oncogenic driver genes have the potential to identify novel biomarkers and drug targets with prognostic and therapeutic value. We effectively integrated metabolomics and gene expression data from breast cancer mouse models through a novel unbiased correlation-based network analysis. This approach identified 35 metabolite and 34 gene hubs with the most network correlations. These hubs have prognostic value and are likely integral to tumor metabolism and breast cancer. We focused on the gene hub Aquaporin-7 (human AQP7/mouse Aqp7), a water and glycerol channel, as a novel regulator of breast cancer. We identified AQP7 as a negative prognostic marker of overall survival and metastasis in breast cancer patients. Both in vitro and in vivo experiments showed that AQP7 is required for proliferation, primary tumor progression, and metastasis. Metabolomics on Aqp7 knockdown cells and tumors revealed significantly altered lipid levels, redox, and urea/arginine metabolism. Given the correlation of AQP7 with breast cancer and its involvement in glycerol transport and lipid homeostasis, we investigated AQP7 as a metabolic target for cancer therapy. We find that AQP7 is a critical regulator of metabolic and signaling responses to environmental cellular stresses and of endocrine therapy efficacy in breast cancer metastasis to lung. Our data support AQP7 expression being higher in tumors from breast cancer patients that do not respond to endocrine therapy compared to those that do respond. We investigated whether AQP7 inhibition can increase the therapeutic efficacy of endocrine therapy in breast cancer. Interestingly, we see therapeutic synergy between the aquaporin inhibitor Auphen and endocrine therapy tamoxifen, which suggests that Auphen treatment makes the cells more susceptible to tamoxifen. Aqp7 is a novel therapeutic target that provides a metabolic vulnerability in breast cancer and can be targeted to inhibit breast cancer metastasis in combination with endocrine therapy. Together, this study highlights AQP7 as a potential cancer-specific therapeutic vulnerability, and AQP7 inhibition can be exploited for therapeutic benefit in overcoming endocrine therapy resistance.We find that Aqp7 regulates the lower TCA cycle and does not play a key role in the flux of metabolites through glycolysis. Increased expression of hAQP7/mAqp7 significantly alter gene expression, particularly in genes involved in cell proliferation, migration, and response to DNA damage. Structure-function analysis of conserved structural features of Aqp7 plays a role in maintaining metabolic homeostasis. Additionally, these structural features may contribute to additional cancer phenotypes like proliferation and adhesion. Together, this study provides new insight into how AQP7 alters metabolism and AQP7 structure-function relationships, which will provide information that can be used to develop metabolism-targeting therapies and AQP associated drugs for clinical anticancer therapy.

English

ISBN: 9798381153095Subjects--Topical Terms:

518028
Biochemistry.
Subjects--Index Terms:

Aquaporin

The Effect of Aquaporin-7 on Breast Cancer Progression and Therapeutic Resistance /
LDR:04470nmm a22004213i 4500 001 2400472
005 20250522084134.5
006 m o d
007 cr|nu||||||||
008 251215s2024 miu||||||m |||||||eng d
020 $a 9798381153095
035 $a (MiAaPQD)AAI30689683
035 $a AAI30689683
040 $a MiAaPQD $b eng $c MiAaPQD $e rda
100 1 $a Charlestin, Verodia, $e author. $3 3770478
245 1 0 $a The Effect of Aquaporin-7 on Breast Cancer Progression and Therapeutic Resistance / $c Verodia Charlestin.
264 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2024
300 $a 1 electronic resource (289 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 85-06, Section: B.
500 $a Advisors: Littlepage, Laurie E. Committee members: Serianni, Anthony S; Blagg, Brian.
502 $b Ph.D. $c University of Notre Dame $d 2024.
520 $a The complex yet interrelated connections between cancer metabolism, gene expression, and oncogenic driver genes have the potential to identify novel biomarkers and drug targets with prognostic and therapeutic value. We effectively integrated metabolomics and gene expression data from breast cancer mouse models through a novel unbiased correlation-based network analysis. This approach identified 35 metabolite and 34 gene hubs with the most network correlations. These hubs have prognostic value and are likely integral to tumor metabolism and breast cancer. We focused on the gene hub Aquaporin-7 (human AQP7/mouse Aqp7), a water and glycerol channel, as a novel regulator of breast cancer. We identified AQP7 as a negative prognostic marker of overall survival and metastasis in breast cancer patients. Both in vitro and in vivo experiments showed that AQP7 is required for proliferation, primary tumor progression, and metastasis. Metabolomics on Aqp7 knockdown cells and tumors revealed significantly altered lipid levels, redox, and urea/arginine metabolism. Given the correlation of AQP7 with breast cancer and its involvement in glycerol transport and lipid homeostasis, we investigated AQP7 as a metabolic target for cancer therapy. We find that AQP7 is a critical regulator of metabolic and signaling responses to environmental cellular stresses and of endocrine therapy efficacy in breast cancer metastasis to lung. Our data support AQP7 expression being higher in tumors from breast cancer patients that do not respond to endocrine therapy compared to those that do respond. We investigated whether AQP7 inhibition can increase the therapeutic efficacy of endocrine therapy in breast cancer. Interestingly, we see therapeutic synergy between the aquaporin inhibitor Auphen and endocrine therapy tamoxifen, which suggests that Auphen treatment makes the cells more susceptible to tamoxifen. Aqp7 is a novel therapeutic target that provides a metabolic vulnerability in breast cancer and can be targeted to inhibit breast cancer metastasis in combination with endocrine therapy. Together, this study highlights AQP7 as a potential cancer-specific therapeutic vulnerability, and AQP7 inhibition can be exploited for therapeutic benefit in overcoming endocrine therapy resistance.We find that Aqp7 regulates the lower TCA cycle and does not play a key role in the flux of metabolites through glycolysis. Increased expression of hAQP7/mAqp7 significantly alter gene expression, particularly in genes involved in cell proliferation, migration, and response to DNA damage. Structure-function analysis of conserved structural features of Aqp7 plays a role in maintaining metabolic homeostasis. Additionally, these structural features may contribute to additional cancer phenotypes like proliferation and adhesion. Together, this study provides new insight into how AQP7 alters metabolism and AQP7 structure-function relationships, which will provide information that can be used to develop metabolism-targeting therapies and AQP associated drugs for clinical anticancer therapy.
546 $a English
590 $a School code: 0165
650 4 $a Biochemistry. $3 518028
650 4 $a Oncology. $3 751006
650 4 $a Pharmacology. $3 634543
653 $a Aquaporin
653 $a Breast
653 $a Cancer
653 $a Metabolism
690 $a 0487
690 $a 0992
690 $a 0419
710 2 $a University of Notre Dame. $b Chemistry and Biochemistry. $e degree granting institution. $3 3770479
720 1 $a Littlepage, Laurie E. $e degree supervisor.
773 0 $t Dissertations Abstracts International $g 85-06B.
790 $a 0165
791 $a Ph.D.
792 $a 2024
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=30689683